Real-World Experience on the Use of Eravacycline at Doses of 1 mg/kg Bodyweight and Fixed Dose Strategy in Two European Tertiary Centers
Eravacycline represents a possible therapeutic option for a wide range of pathogens, but its use must be evaluated in the context of infection site and severity.
Authors
- Chiara Moreal (ORCID: https://orcid.org/0000-0001-7926-7581)
- Jacopo Angelini (ORCID: https://orcid.org/0000-0002-8433-0394)
- Matthias G. Vossen (ORCID: https://orcid.org/0000-0002-4350-7173)
- Miriam M. Moser (ORCID: https://orcid.org/0009-0007-5317-1881)
- Heinz Burgmann (ORCID: https://orcid.org/0000-0002-2114-0999)
- Simone Giuliano (ORCID: https://orcid.org/0000-0003-2475-8732)
- Lisa Schneider (ORCID: https://orcid.org/0000-0002-8928-4702)
- K. Oberreiter
- Carlo Tascini
Institutions
- University of Udine (IT)
- Ospedale Santa Maria della Misericordia di Udine (IT)
- Medical University of Vienna (AT)
Publication Details
- Journal
- Antibiotics
- Published
- 2026-04-21
- DOI
- https://doi.org/10.3390/antibiotics15040421
- Primary Topic
- Pharmaceutical and Antibiotic Environmental Impacts
- Type
- article
- Field-Weighted Citation Impact
- 0.00